Welcome to our dedicated page for Olema Pharmaceuticals SEC filings (Ticker: OLMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Olema Pharmaceuticals, Inc. filings document the regulatory record of a clinical-stage oncology company with common stock listed on the Nasdaq Global Select Market under OLMA. The company’s disclosures cover its targeted-therapy pipeline, including palazestrant and OP-3136, as well as financial results, liquidity updates, capital-structure matters, and Regulation FD investor materials.
Olema’s SEC filings also record material agreements, including lease arrangements, and governance matters such as board appointments, officer departures, indemnification agreements, compensation arrangements, and equity awards. Proxy materials address director elections, executive compensation, equity incentive plans, pay-versus-performance disclosure, and shareholder voting matters.
Olema Pharmaceuticals director Cyrus Harmon reported selling a total of 25,000 shares of common stock in open-market or private transactions on July 23 and 24, 2026, at weighted average prices of $11.579 and $11.714 per share, respectively. An additional 117,028 shares are reported as held indirectly by Harmon Family Investors LLC, where Harmon is the manager.
Cyrus L. Harmon filed to sell 12,500 common shares of OLMA through Fidelity Brokerage Services LLC on July 24, 2026 on NASDAQ, with an indicated value of $146,419.49. The filing also reports that Harmon sold 12,500 common shares on July 23, 2026 for $144,737.53, originally acquired as founders shares on March 20, 2007 as compensation.
Olema Pharmaceuticals director-affiliated investment entities reported updated holdings and a new equity award arrangement. Funds and entities associated with Biotechnology Value Fund and Mark N. Lampert jointly report common stock, stock options and pre-funded warrants and collectively disclaim beneficial ownership beyond their pecuniary interests.
A key update is a grant of 29,500 stock options with an exercise price of $9.51 per share, linked to director Gorjan Hrustanovic. These options vest in 12 equal monthly installments starting June 18, 2026, or sooner at Olema’s next annual stockholder meeting if not already fully vested, subject to his continued service.
The filing also lists substantial pre-funded warrants, each exercisable for one share of common stock at $0.0001 per share, subject to a 9.99% ownership cap to limit how many shares can be held immediately after any exercise.
Olema Pharmaceuticals director Harmon Cyrus received a grant of stock options covering 29,500 shares of common stock. The options have an exercise price of $9.51 per share and expire on June 18, 2036. Following this grant, Cyrus holds 29,500 stock options directly.
The options vest in 12 equal monthly installments starting June 18, 2026, conditioned on continued service. Any unvested portion will fully vest on the date of Olema’s next annual meeting of stockholders if not already fully vested, also subject to continued service.
Olema Pharmaceuticals director Cynthia M. Butitta received a grant of 29,500 stock options for common stock. The options have an exercise price of $9.51 per share and were awarded as compensation, not through an open-market purchase.
The options vest in 12 equal monthly installments starting on June 18, 2026, as long as she continues in service. Any unvested portion will fully vest on the date of Olema’s next annual meeting of stockholders if the grant is not already fully vested by then.
Olema Pharmaceuticals director Garland J. Scott received a grant of stock options covering 29,500 shares of common stock. The options have an exercise price of $9.51 per share and expire on June 18, 2036. Following this grant, Scott holds options for 29,500 shares directly.
The options vest in 12 equal monthly installments starting on June 18, 2026, subject to continuous service. Any unvested portion will vest in full on the date of Olema’s next annual stockholder meeting if the option is not already fully vested by then.
Olema Pharmaceuticals director Gorjan Hrustanovic received a grant of stock options for 29,500 shares of common stock at an exercise price of $9.51 per share. The options expire on June 18, 2036 and vest in 12 equal monthly installments starting June 18, 2026, with any remaining unvested portion vesting in full on the date of Olema’s next annual stockholder meeting if not already fully vested, subject to his continued service. Under a pre-existing arrangement, any economic benefit from the sale of shares issued upon exercise is payable to BVF Partners L.P., and Hrustanovic disclaims beneficial ownership except for any pecuniary interest.
Olema Pharmaceuticals director Ian T. Clark received a new stock option grant. The award covers 29,500 shares of common stock at an exercise price of $9.51 per share and expires on June 18, 2036. The option vests in 12 equal monthly installments starting on June 18, 2026, with all remaining unvested shares vesting earlier on the date of Olema’s next annual stockholder meeting if it occurs sooner, in each case subject to his continued service.
Olema Pharmaceuticals director Yi Larson received a grant of stock options covering 29,500 shares of Common Stock. The options have an exercise price of $9.51 per share and expire on June 18, 2036.
The 29,500 options vest in 12 equal monthly installments measured from June 18, 2026, subject to continued service. Any unvested options will instead fully vest on the date of Olema’s next annual meeting of stockholders, if earlier and if service continues through that date.